A5065113263- Prostate Cancer Treatment and Research
- Lung Cancer Treatments and Mutations
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Cell death mechanisms and regulation
- Radiopharmaceutical Chemistry and Applications
- Chronic Myeloid Leukemia Treatments
- Prostate Cancer Diagnosis and Treatment
- Cancer Research and Treatments
- Head and Neck Cancer Studies
- Peptidase Inhibition and Analysis
- Advanced Breast Cancer Therapies
- Hemophilia Treatment and Research
- Eosinophilic Disorders and Syndromes
- Ubiquitin and proteasome pathways
- Microtubule and mitosis dynamics
- BRCA gene mutations in cancer
- Lymphoma Diagnosis and Treatment
- Toxin Mechanisms and Immunotoxins
CancerCare
2022-2024
Tennessee Oncology
2023-2024
Memorial Sloan Kettering Cancer Center
2024
Mayo Clinic in Arizona
2024
Dana-Farber Cancer Institute
2024
University Hospital Münster
2024
Indiana University – Purdue University Indianapolis
2024
Université Paris-Saclay
2024
Indiana University Health
2024
Cornell University
2024
5002 Background: In the phase 3 VISION study, gallium ( 68 Ga) gozetotide Ga-PSMA-11) PET/CT imaging was used to determine eligibility for lutetium 177 Lu) vipivotide tetraxetan Lu-PSMA-617). Given that Lu-PSMA-617 targets PSMA, we assessed association between quantitative PSMA parameters and treatment outcomes. Methods: VISION, adults with mCRPC ≥ 1 PSMA-positive (+) no PSMA-negative lesions meeting exclusion criteria were enrolled. this sub-study, data from pre-enrollment Ga-PSMA-11 scans...
Background Lutetium 177 [
BRCA1 is a susceptibility gene for breast and ovarian cancer with growth-inhibitory activity which the mechanism of action remains unclear. When introduced into cells, inhibits growth some but not all cell lines. In an attempt to uncover suppression by , we examined panel lines their ability reduce colony outgrowth in response overexpression. Of variables tested, only those cells wild-type pRb were sensitive -induced suppression. intact rb gene, inactivation HPV E7 abrogates arrest imposed ....
BRCA1 gene is a tumor suppressor for breast and ovarian cancers with the putative role in DNA repair transcription. To characterize of transcriptional regulation, we analyzed expression profiles mouse embryonic stem cells deficient using microarray technology. We found that loss correlated decreased several groups genes including stress response genes, cytoskeleton involved protein synthesis degradation. Previous study showed co-activator p53 protein; however majority target remained at same...
9610 Background: First-line immunotherapy with/without chemotherapy is standard of care for patients (pts) with advanced NSCLC; however, there a need effective treatment options after progression on prior immune checkpoint inhibitor (ICI). Cabozantinib (C) may augment response to ICI by inhibiting kinases implicated in suppressing cell responses and has shown encouraging clinical activity combination other tumor types including RCC HCC. COSMIC-021, multicenter phase 1b study, evaluating the...
9005 Background: C, a multitargeted receptor tyrosine kinase inhibitor (TKI), promotes an immune-permissive environment that may enhance ICI activity. COSMIC-021 (NCT03170960) is multicenter phase 1b study evaluating C + A in advanced solid tumors. In COSMIC-021, demonstrated encouraging clinical activity the cohort of pts with aNSCLC previously treated ICIs (cohort 7 [C7]) (Neal. ASCO 2020. Abstr 9610). Updated outcomes expanded C7 and for alone exploratory 20 (C20) are presented. Methods:...
Aim: A retrospective chart review of ibrutinib-treated patients with chronic lymphocytic leukemia (CLL) was conducted. Patients & methods: Adults CLL who initiated ibrutinib were followed for ≥6 months (n = 180). Results: Twenty-five percent first-line experienced ≥1 dose reduction, mainly due to adverse events (AEs; 79%). Treatment discontinuations and holds occurred in 20 34% patients, respectively, most commonly AEs (73 74%). Approximately one-quarter relapsed/refractory (88%)....
To report the safety and efficacy of ipatasertib (AKT inhibitor) combined with rucaparib (PARP in patients metastatic castration-resistant prostate cancer (mCRPC) previously treated second-generation androgen receptor inhibitors.In this two-part phase Ib trial (NCT03840200), advanced prostate, breast, or ovarian received (300 400 mg daily) plus (400 600 twice to assess identify a recommended II dose (RP2D). A part 1 dose-escalation was followed by 2 dose-expansion which only mCRPC RP2D. The...
The aim of this study is to investigate the impact missed chemotherapy administrations (MCA) on prognosis non-small cell lung cancer (NSCLC) patients treated with definitive chemoradiation therapy (CRT).In total, 97 NSCLC CRT were assessed for MCA due toxicities. Logistic regression was used determine factors associated MCA. Kaplan-Meier curves, log-rank tests, and Cox Proportional Hazards models conducted.MCA occurred in 39% (n=38) patients. Median overall survival 9.6 months compared 24.3...
A recent real-world study observed that 24% of patients with advanced non-small cell lung cancer (aNSCLC) actionable driver oncogenes (ADOs) initiated nontargeted therapies before biomarker test results became available. This assessed the clinical impact timing first-line (1L) targeted (TTs) in aNSCLC.
Amivantamab (ami) is an EGFR-MET bispecific antibody with immune cell-directing activity. In MARIPOSA-2 (NCT04988295), ami plus carboplatin-pemetrexed (ami-chemo) significantly prolonged progression-free survival (PFS) vs chemo in patients (pts) EGFR-mutant advanced NSCLC after progression on osimertinib (Passaro Ann Oncol 2023). Post-progression outcomes from were assessed. 657 pts randomized. These analyses focus the 131 randomized to ami-chemo (safety: n=130) and 263 n=243). A third arm...
720 Background: Pancreatic cancer claimed an estimated 47,050 lives in the USA 2020, with expected median overall survival (OS) of 3 months 3rd line. (Manax ASCO GI 2019), no evidence disease control these late stage patients. We hypothesize that effective response against pancreatic requires orchestration both innate and adaptive immune system to accomplish immunogenic cell death benefit. Herein we report updated results fully enrolled cohort a novel combination immunotherapy protocol...
TPS3635 Background: Treatment options for most patients with metastatic colorectal cancer (mCRC) are largely limited to cytotoxic chemotherapy, little advancement in the last decade. Encouragingly, a small subset of deficient mismatch repair (dMMR/MSI-hi) benefit from checkpoint inhibitors (CPI) whereas those proficient (pMMR/MSS) do not. The absence clinical pMMR/MSS mCRC may relate lack neoantigen-specific T cells and immune infiltration. An individualized neoantigen vaccine that induces...
Despite recent approvals of lifesaving treatments for chronic lymphocytic leukemia (CLL), real-world data on the tolerability Bruton tyrosine kinase inhibitor ibrutinib CLL treatment are lacking, especially in Black patients. To expand upon a previously reported retrospective chart review ibrutinib-treated patients with to increase number sites and enrollment period first-line (1L) relapsed/refractory (R/R) settings subanalysis based ethnicity. Adults who initiated from five centers were...
95 Background: mCRPC remains an incurable disease with unmet need for improved therapies. PARP inhibition has demonstrated antitumor activity, and preclinical studies suggest synergy between AKT inhibition. This phase Ib trial (NCT03840200) sought to determine the maximum tolerated dose of inhibitor rucaparib (ruca) ipatasertib (ipat) explore early safety efficacy in patients (pts) mCRPC. Methods: The study had 2 parts: a part 1 dose-escalation (cohort [C]1: ipat 300 mg QD + ruca 400 BID;...
The occurrence of factor VIII inhibitors in non-hemophilic patients is a rare event with potentially lethal outcome. Despite its infrequent occurrence, the association this inhibitor multiple autoimmune diseases well recognized. We report case patient recently described lymphoproliferative syndrome (ALPS) who developed an to VIII. ALPS disease characterized by defective lymphocyte apoptosis due inherited mutations genes that regulate apoptosis, resulting enlargement lymphoid organs and...
TPS2623 Background: ONC201 is an orally active first-in-class small molecule with strong antitumor activity in preclinical models of advanced cancers. In cancer cell lines and patient samples induces integrated stress response (Ishizawa et al, 2014), late-stage inactivation Akt ERK, downstream activation the apoptotic TRAIL pathway as part innate immune surveillance (Allen J Sci Trans Med, 2013). Activity independent p53 status. well tolerated at efficacious doses animal models, crosses...
Aim: Biomarker testing detects actionable driver mutations to inform first-line treatment in advanced non-small-cell lung cancer (aNSCLC) and metastatic colorectal (mCRC). This study evaluated biomarker a nationwide database (NAT) versus the OneOncology (OneOnc) community network. Patients & methods: with aNSCLC or mCRC ≥1 test de-identified electronic health record-derived were evaluated. OneOnc oncologists surveyed. Results: rates high comparable between NAT; next-generation sequencing...
2514 Background: ONC201 is an orally active, first-in-class small molecule activator of the integrated stress response that selectively upregulates ATF4 to trigger tumor cell death. Preclinical studies have established compelling antitumor efficacy in a range advanced solid tumors as well its excellent safety profile animals. A first-in-human phase I study was conducted determine recommended II dose (RP2D) patients with tumors. Methods: This open-label treated 10 during single-patient cohort...
Abstract Background: HER2-targeted therapies have led to marked improvements in survival for patients with HER2-positive breast cancer. Despite the gains obtained current therapies, an unmet medical need remains HER2-expressing (high or low expression) advanced cancer that has progressed after prior treatments. Zanidatamab is a novel bispecific antibody multiple mechanisms of action, including immune clearance tumor cells through antibody-dependent cellular phagocytosis. been shown be...